[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-infarction":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,116,0,25,[9,41,58,84,106,132,165,191,226,252,273,303,329,353,389,419,447,496,519,547,574,605,632,658,679],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100387190","study-of-circulating-monocytes-in-patients-with-ischemic-vascular-disease-100387190",false,"NCT04321512","Study of Circulating Monocytes in Patients With Ischemic Vascular Disease","Inclusion Criteria:\n\n* STEMI Patients: Men and women aged 18 years and over, with symptoms, physical signs and ECG changes characteristic of STEMI.\n* NSTEMI Patients: Men and women aged 18 years and over, with symptoms, physical signs and ECG changes characteristic of NSTEMI.\n* Stable CAD Patients: men and women aged 18 years and older with coronary artery disease proven by prior MI history, angiography or stress test but without any unstable angina or acute coronary syndrome.\n* Ischemic Stroke Patients: Men and women aged 18 years and over, with symptoms, physical signs and CT\u002FMRI changes characteristic of ischemic stroke.\n* Healthy Controls: Men and women aged 18 years and over, without heart failure, coronary disease, hypertension, diabetes or other chronic diseases. Control subjects will be recruited from within the community of UConn Health via advertisement.\n\nExclusion Criteria:\n\n* Subjects who are unable to give informed consent (with the exception of the ischemic stroke arm patients, see Protocol Design below) and pregnant subjects.\n* Subjects who had any history of embolic, ischemic or hemorrhagic stroke within the last 12 months.",true,"ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to discover the functions of circulating white blood cells, called monocytes, and associated circulating substances in heart attack and ischemic stroke patients. Ischemic Strokes (clots) occur as a result of an obstruction within a blood vessel supplying blood to the brain. A type of monocyte carrying a surface marker called \"P2X4\" helps the immune system sense and respond to danger signals from the body such as heart muscle and brain tissue injuries.\n\nThe researchers expect to learn more about how these monocyte cells react to heart and brain tissue injury, and how the cells may then produce proteins or other chemical substances which promote the healing of heart muscle after heart attack and brain tissue after an ischemic stroke.",[25,26,27],"Myocardial Infarction","Stroke, Ischemic","Ischemia","RECRUITING","2026-08-14",{"date":31,"type":32},"2026-08-17","ACTUAL",{"date":34,"type":32},"2013-12-01",{"date":36,"type":21},"2027-12-01",{"name":38,"class":39},"UConn Health","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":40},"100114995","circulating-markers-for-ischemic-heart-disease-100114995","NCT00762333","Circulating Markers for Ischemic Heart Disease","Inclusion Criteria:\n\n* men and women, 18 years of age and over with acute myocardial infarction (determined by positive cardiac markers -CKMB\u002F troponin) with or without heart failure (dyspnea, rales, edema, elevated jugular venous pressure, ascites).\n* Heart failure can be diagnosed using imaging evidence such as dilated heart, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures\n* A control group of male subjects age 60 and older without history of MI or heart disease\n\nExclusion Criteria:\n\n* Subjects unable to give consent\n* Subjects who have undergone cardiac or non-cardiac surgery in the 3 months prior to enrollment",{"count":48,"type":21},550,"The purpose of this research is to determine if two proteins in the blood are increased during acute myocardial infarction and whether their levels are higher in those who develop heart failure than those who do not. These two proteins are produced and potentially released when the heart muscle is damaged. They may then be released into the blood and be detected by standard method in the research laboratory. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or myocardial infarction.",[25,27,51],"Congestive Heart Failure",{"date":31,"type":32},{"date":54,"type":32},"2007-06",{"date":56,"type":21},"2027-03",{"name":38,"class":39},{"id":59,"slug":60,"hasResults":12,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":40},"100651843","innate-immune-cell-phenotypes-and-early-fibrotic-repair-in-acute-myocardial-infarction-100651843","NCT07764588","Innate Immune Cell Phenotypes and Early Fibrotic Repair in Acute Myocardial Infarction","ICE-AMI","Inclusion Criteria:\n\n\\---- Age \\> 18 and ≤ 80 years old\n\n\\- Patients with acute STEMI within 12 hours of symptom onset who are planned to receive PPCI\n\nExclusion Criteria:\n\n* Prior revascularization\n* Known allergy to gadopentetate dimeglumine contrast agent\n* Pregnancy or planned pregnancy within the next 6 months\n* Life expectancy \\\u003C 1 year\n* Metallic implants or claustrophobia that precluded MRI\n* Severe COPD or inability to hold breath for MRI\n* Severe hepatic or renal dysfunction (ALT \\> 5×ULN or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73 m²)","80 Years",{"count":67,"type":21},50,"To determine the relationship of the phenotypes of neutrophils and monocytes with early fibrotic repair after acute myocardial infarction.",[25],[71,72,73,74,75],"neutrophil","monocyte","myocardial infarction","cardiac remodeling","cardiac magnetic resonance","2026-08-12",{"date":29,"type":32},{"date":79,"type":32},"2026-01-01",{"date":81,"type":21},"2026-12-31",{"name":83,"class":39},"Shanghai 10th People's Hospital",{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":40},"100532201","vegetarian-diet-and-innate-immunity-in-patients-with-myocardial-infarction-and-in-healthy-volunteers-fresh-mi-study-100532201","NCT06209723","Vegetarian Diet and Innate Immunity in Patients With Myocardial Infarction and in Healthy Volunteers (FRESH-MI Study)","Effect of a Vegetarian Diet on Innate Immunity in Patients With Myocardial Infarction and in Healthy Volunteers (FRESH-MI Study)","FRESH-MI","Inclusion Criteria for patients:\n\n* Acute myocardial infarction (STEMI\u002FNSTEMI) with a clear culprit lesion on angiography and successful primary percutaneous coronary intervention (PCI) \\\u003C1 week before randomisation\n* Body mass index between 18.5 and 35 kg\u002Fm2\n* Written informed consent\n\nInclusion Criteria for healthy volunteers (life partners \u002F souses)\n\n* Body mass index between 18.5 and 35 kg\u002Fm2\n* Written informed consent\n\nExclusion Criteria for patients and healthy volunteers:\n\n* Already on a vegetarian or vegan diet\n* Previous myocardial infarction\n* Diabetes Mellitus\n* Medical history of any disease associated with immune deficiency (either congenital or acquired, including chemotherapy, chronic steroid use, organ transplant)\n* Use of immunomodulatory drugs\n* Vaccination less than one month before start of intervention\n* Clinically significant infections within 1 months prior to start of intervention (defined as fever \\>38.5 degrees Celsius)\n* Active malignant haematological disease\n* Known eating disorder (e.g., Anorexia nervosa, Bulimia nervosa)\n\nExclusion Criteria for healthy volunteers\n\n\\- Use of lipid lowering therapy",{"count":93,"type":21},120,"INTERVENTIONAL",[96],"NA","The goal of this clinical trial is to assess the effect of a vegetarian diet on innate immunity of patients with a recent acute myocardial infarction and healthy participants. Also, we will assess the willingness to adapt a more vegetarian eating habit. Study subjects will follow a vegetarian diet for five weeks, whereafter a stabilisation period of six weeks will follow. Then, participants will follow to the other dietary intervention for five weeks. Blood will be drawn at given time points to analyse inflammatory parameters.",[25],{"date":29,"type":32},{"date":101,"type":32},"2024-01-26",{"date":103,"type":21},"2027-09-01",{"name":105,"class":39},"Radboud University Medical Center",{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":131},"100603880","evaluation-of-1-year-clinical-outcomes-with-early-inclisiran-initiation-in-post-mi-patients-100603880","NCT07142265","Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients","STREAMLINE","Inclusion Criteria:\n\n* Adult patients of both genders\n* Myocardial Infarction diagnosis\n* Dyslipidemia diagnosis\n* The first injection of inclisiran no later than 14 ± 5 days after the STEMI\u002Fnon-STEMI\n* LDL-C \\> 5 mmol\u002FL (statin-naive patients) or LDL-C \\> 2.5 mmol\u002FL (on the basis of statin MTD) at the time of hospitalization or no target LDL-C level (\\> 1.4 mmol\u002FL or no LDL-C level decrease by 50% on statin MTD + ezetimibe)\n* Signed Informed Consent Form (ICF)\n\nExclusion Criteria:\n\n* Severe oncological and somatic diseases with system and organ failure\\*\n* Competing diseases that caused emergency hospitalization (pulmonary thromboembolism, aortic dissection)\n* History of therapy with PCSK9 inhibitors\n* Active inflammatory liver disease or the levels of AST, ALT \\> 3 times, or total bilirubin \\> 2 times higher than the upper limit of norm\n* Any other MACE in the anamnesis","100 Years",{"count":20,"type":21},"Evaluation of clinical outcomes during 12 months after inclisiran initiation in patients after STEMI\u002Fnon-STEMI in real-world settings in Russia. It is also planned to study the therapy effect on the lipid profile characteristics, its safety, the state of atherosclerotic plaques according to carotid ultrasound, the frequency of hospitalizations and the need for intensive follow-up.",[25],[118,119,120],"Myocardial infarction","NIS","inclisiran","2026-08-06",{"date":123,"type":32},"2026-08-10",{"date":125,"type":32},"2025-09-30",{"date":127,"type":21},"2027-09-30",{"name":129,"class":130},"Novartis Pharmaceuticals","INDUSTRY",18,{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":94,"phases":142,"briefSummary":143,"conditions":144,"keywords":149,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100648980","rapid-or-ultra-rapid-diagnosis-of-myocardial-infarction-using-high-sensitivity-cardiac-troponin-on-hospital-presentation-100648980","NCT07727135","Rapid or Ultra-rapid Diagnosis of Myocardial Infarction Using High-Sensitivity Cardiac Troponin on Hospital Presentation","Danish Randomized Trial of Rapid or Ultra-rapid Diagnosis of Myocardial Infarction Using High-Sensitivity Cardiac Troponin on Hospital Presentation","DanRUSH","Inclusion Criteria:\n\n* Adults (≥18 years) presenting with suspected acute coronary syndrome (ACS) with a clinical indication for high-sensitivity cardiac troponin testing\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* ST-segment elevation myocardial infarction (STEMI) identified on the presenting electrocardiogram and requiring immediate reperfusion therapy.",{"count":141,"type":21},28000,[96],"People with chest pain are often tested for a heart attack using a blood test called high-sensitivity cardiac troponin (hs-cTn). Traditionally, this blood test is repeated 3 hours after the first sample. Newer guidelines recommend repeating the test after 1 hour instead, which may allow patients to receive a diagnosis and leave the hospital sooner.\n\nThe purpose of the DanRUSH trial is to compare these two strategies: repeating the blood test after 1 hour versus after 3 hours in adults with suspected acute coronary syndrome. The study will evaluate whether the 1-hour strategy is as safe as the 3-hour strategy while reducing the length of hospital stay.\n\nDanRUSH is a nationwide, pragmatic, cluster-randomized trial conducted in emergency- and cardiology departments across Denmark. The results will help determine the best timing for blood testing in patients with suspected heart attack and improve future care for these patients.",[145,25,146,147,148],"Coronary Syndrome, Acute","Coronary Artery Disease","Cardiovascular Diseases","Cardiovascular Disease Acute",[118,150,151,152,153,154],"Troponin","Biomarker","Clinical assessment","Myocardial injury","Coronary syndrome","NOT_YET_RECRUITING","2026-08-04",{"date":121,"type":32},{"date":159,"type":21},"2026-09-01",{"date":161,"type":21},"2029-02-01",{"name":163,"class":39},"Herlev and Gentofte Hospital",11,{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":94,"phases":175,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":40},"100635176","phase-4-intranasal-dexmedetomidine-and-perioperative-myocardial-injury-100635176","NCT07549282","Intranasal Dexmedetomidine and Perioperative Myocardial Injury","Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary Interventions: A Single-Center, Prospective Randomized Controlled Pilot Study","Inclusion Criteria:\n\n* Aged between 18 and 85 years old;\n* Subjects are fully informed of the risks, benefits and alternative treatment regimens of intranasal dexmedetomidine administration. Written informed consent is signed by the subject themselves or their legal representative prior to any study-related procedures;\n* Confirmed diagnosis of coronary artery disease with objective evidence of myocardial ischemia or silent myocardial ischemia, and indications for elective percutaneous coronary intervention (PCI);\n* American Society of Anesthesiologists (ASA) physical status classification II to III (patients with mild to severe systemic underlying diseases; ordinary physical activities are markedly limited, yet mild daily activities can be performed).\n\nExclusion Criteria:\n\n* Subjects with hypersensitivity or contraindications to dexmedetomidine, including severe sinus bradycardia (resting heart rate \\\u003C50 beats per minute), sick sinus syndrome, and second-degree or higher atrioventricular block without pacemaker implantation;\n* Severe cardiac dysfunction (left ventricular ejection fraction \\\u003C40%), New York Heart Association (NYHA) class III-IV heart failure, cardiogenic shock, or hemodynamic instability;\n* Poorly controlled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg), or hypotension (systolic blood pressure \\\u003C90 mmHg);\n* Coexisting obstructive sleep apnea hypopnea syndrome (OSAHS);\n* Body mass index (BMI) \\>30 kg\u002Fm²;\n* Use of agents that may interfere with the study drug within 1 week before surgery, including α₂ adrenergic receptor agonists (e.g., clonidine), receptor antagonists, and tricyclic antidepressants;\n* Cognitive assessment cannot be completed due to language, visual or hearing impairment;\n* Hepatic or renal insufficiency (alanine aminotransferase, aspartate aminotransferase, or serum creatinine exceeding 3 times the upper limit of normal reference values);\n* Nasal anatomical abnormalities that preclude intranasal spray administration;\n* Pregnant or breastfeeding women;\n* Participation in other conflicting clinical trials.","85 Years",{"count":174,"type":21},140,[176],"PHASE4","PCI is the standard treatment for CAD, yet perioperative myocardial injury occurs frequently in nearly 40% of patients. Perioperative stress and sympathetic overactivation break myocardial oxygen balance and lead to cardiac damage, which further raises short-term cardiovascular events and long-term mortality risks. Dexmedetomidine exerts cardioprotective effects by inhibiting sympathetic excitation, though intravenous use carries risks of hypotension and bradycardia. Intranasal dexmedetomidine shows equivalent efficacy with fewer side effects and better patient compliance. Since no standard perioperative anesthesia regimen exists for elective PCI patients and the clinical benefits of dexmedetomidine remain unconfirmed, this pilot study is designed to test the feasibility and safety of intranasal dexmedetomidine spray before launching large formal RCTs.",[179,180,25,181],"Coronary Heart Disease","Myocardial Injury","Dexmedetomidine","2026-07-29",{"date":184,"type":32},"2026-07-30",{"date":186,"type":21},"2026-08",{"date":188,"type":21},"2027-02",{"name":190,"class":39},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":94,"phases":201,"briefSummary":202,"conditions":203,"keywords":209,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":40},"100647358","evaluation-of-a-remote-behavioural-stress-recovery-intervention-for-myocardial-infarction-patients-younger-than-fifty-five-brim-55-a-feasibility-study-100647358","NCT07706816","Evaluation of a Remote Behavioural Stress Recovery Intervention for Myocardial Infarction Patients Younger Than Fifty-five (BRIM-55): A Feasibility Study","BRIM-55","Inclusion criteria:\n\n* Myocardial infarction (MI) before age 55 years\n* MI within one year prior to randomization\n* Report of subjective cardiac distress in the initial interview\n\nExclusion criteria:\n\n* Serious conditions hindering participation (e.g., active substance misuse, severe mental illness)\n* Insufficient Swedish proficiency for study procedures,\n* Disability pension or early retirement at the time of MI","55 Years",{"count":200,"type":21},30,[96],"The goal of this feasibility study is to learn if the randomised controlled trial evaluating the Remote-delivery Balance in Everyday Life (rBEL) programme for adults younger than 55 years who have experienced a myocardial infarction (MI), is feasible.\n\nThe objective is to examine the feasibility of the rBEL programme and the associated study procedures before a controlled evaluation of the programme. This is an uncontrolled, single-arm, pre-post treatment designed study.\n\nParticipants of the target population will take part of the six session over 13 week programme. Feasibility will be evaluated against predefined feasibility criteria regarding study procedures and programme acceptability.",[204,205,206,25,207,208],"Cardiac Disease","Depression and Quality of Life","Cardiac Distress","Psychological Distress","Anxiety",[210,211,212,213,214,215,216],"Cardiac distress","Heart Attack","Cognitive Behavioral Therapy","Secondary Prevention","Cardiac Rehabilitation","Stress Recovery","Behavioral Intervention","2026-07-15",{"date":219,"type":32},"2026-07-16",{"date":221,"type":21},"2026-08-24",{"date":223,"type":21},"2027-06-30",{"name":225,"class":39},"Uppsala University",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":94,"phases":236,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":40},"100645491","individualized-discharge-education-in-high-risk-myocardial-infarction-patients-100645491","NCT07701109","Individualized Discharge Education in High-Risk Myocardial Infarction Patients","The Effect of Individualized Discharge Education on Readmission Rates in a High-Risk Population According to the LACE Index After Myocardial Infarction","MI","Inclusion Criteria:\n\n* Being over 18 years of age,\n* Not having a cognitive disorder,\n* Not having a history of psychiatric disorders,\n* Being open to communication,\n* Not having hearing, visual or speech impairments,\n* Having a LACE index score of 10 or higher,\n* Being willing to participate in the research.\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Having a LACE index score below 10\n* Not having a cognitive impairment,",{"count":235,"type":21},82,[96],"The purpose of this clinical study is to evaluate whether individualized discharge education is effective in treating patients identified as high-risk based on the LACE index after a myocardial infarction. Additionally, information will be gathered regarding the safety and outcomes of this education. The key questions the study aims to answer are: Does individualized discharge education reduce hospital readmission rates for patients identified as high-risk after a myocardial infarction? Does this education improve patients' treatment adherence, self-care levels, and quality of life? Researchers will compare the effectiveness of individualized discharge education against routine care. Participants will:Receive individualized discharge education prior to discharge if they meet the high-risk criteria, and receive a comprehensive educational brochure. Be followed up via telephone three days a week while at home to monitor their care practices and hospital visits. Participate in follow-up assessments at the 1st month (Follow-up 1) and 3rd month (Follow-up 3) to complete the Coronary Heart Disease Self-Care Inventory and the HeartQoL scale.",[25],[25,240,241,242],"LACE Index","Individualized Discharge Education","Hospital Readmission","2026-07-13",{"date":245,"type":32},"2026-07-14",{"date":247,"type":21},"2026-08-01",{"date":249,"type":21},"2027-08-01",{"name":251,"class":39},"Adiyaman Provincial Health Directorate",{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":94,"phases":261,"briefSummary":262,"conditions":263,"keywords":264,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":269,"leadSponsor":271,"locationsCount":40},"100645827","the-effect-of-virtual-reality-application-diagnosed-with-myocardial-infarction-100645827","NCT07696390","The Effect of Virtual Reality Application Diagnosed With Myocardial Infarction","The Effect of Virtual Reality on Vital Signs and Anxiety in Myocardial Infarction Patients Admitted to Cardiology Intensive Care Unit: A Randomized Controlled Study.","Inclusion Criteria:\n\n1. The patient is in intensive care.\n2. The patient has been diagnosed with myocardial infarction.\n3. The patient is between 18 and 70 years old.\n4. The patient is conscious.\n5. The patient is oriented and cooperative.\n6. The patient volunteers to participate in the study.\n7. The patient is open to communication.\n8. The patient agrees to participate in the study.\n9. The patient has no mental, visual, auditory, or speech impairment.\n10. The patient has undergone stent placement.\n11. The patient has STEMI.\n\nExclusion Criteria:\n\n1. The patient has a psychiatric disorder.\n2. The patient has any communication impairment.","70 Years",{"count":67,"type":21},[96],"This study was designed to investigate the effects of VR (virtual reality) glasses on vital signs and anxiety in conscious patients diagnosed with myocardial infarction and admitted to the cardiology intensive care unit.",[25],[265],"Myocardial infarction, virtual reality, vital signs, stress","2026-07-10",{"date":243,"type":32},{"date":266,"type":32},{"date":270,"type":21},"2026-09-18",{"name":272,"class":39},"Yuzuncu Yil University",{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":281,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":94,"phases":284,"briefSummary":286,"conditions":287,"keywords":291,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":300,"locationsCount":302},"100620809","phase-2-prevention-of-reperfusion-injury-outcomes-through-effective-cardioprotection-targeting-myocardial-infarction-100620809","NCT07362446","Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction","A Randomised, Double-Blind, Placebo-Controlled, Study of Xolatryp in Patients Presenting With STEMI Undergoing Primary PCI","PROTECT-MI","Inclusion Criteria:\n\n* Have provided informed consent.\n* Male patients aged 40 to 75 years of age.- Female patients aged 55 to 75 years of age, or women aged 40 to 55 years that have no possibility of being pregnant.\n* Patient presents with first-time STEMI, scheduled to undergo primary PCI within 6 h of symptom onset and anticipated door to balloon time \\\u003C 2 h.\n* In combination with symptoms consistent with acute MI, patient must demonstrate ST-elevation at the J-point in two contiguous leads.\n* Hemodynamically stable including: systolic BP ≥ 90 mmHg, HR 50-120 bpm.\n* Killip Class I or II.\n* Oxygen saturation ≥ 92% on room air or low-flow oxygen.\n* No ongoing VT\u002FVF at enrolment.\n* Male participants with female partners of child-bearing potential must be ready and able to use highly effective methods of birth control for at least 7 days following IP administration.\n\nExclusion Criteria:\n\n* History or ECG evidence of myocardial infarction or cardiomyopathy.\n* Prior major cardiac surgery, including but not limited to coronary artery bypass graft surgery (CABG).\n* Known contraindication to CMR (e.g. pacemakers, cochlear implants, aneurism clips, claustrophobia, allergy to contrast medium).\n* History of clinically significant renal impairment requiring dialysis or an estimated glomerular filtration rate \\\u003C30 mL\u002Fmin.\n* Estimated or known body weight \\\u003C 50 kg, \\> 120 kg at screening.\n* Concurrent enrolment in another investigational device or drug trial, or less than 30 days or 5 half-lives of investigational device or drug (whichever is longer), since ending another investigational device or drug trial(s) or receiving other investigational treatment(s). Patients who are participating in non-interventional, purely observational trials can be included.\n* Life expectancy of less than 1 year due to non-cardiac pathology in the opinion of the Investigator.\n* Any condition or significant clinical abnormality identified at the time of screening that in the judgment of the Investigator or any sub-Investigator would preclude safe completion of the study.\n* Known history of hypersensitivity to the investigational drug, or excipients, or do not want to be exposed to soy or egg (including products and derivatives).","40 Years","75 Years",{"count":20,"type":21},[285],"PHASE2","This study is open to adults with ST elevation myocardial infarction (heart attack) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study is to determine whether a medicine called Xolatryp is safe and effective in improving cardiac outcomes. One dose of Xolatryp will be tested in this study.\n\nParticipants are put into two groups randomly, which means by chance. One group receives a single 6-hour continuous intravenous infusion of Xolatryp and one group receives placebo. Participants are in the study for about 30 days.\n\nPlacebo infusion looks like Xolatryp but do not contain any medicine. Participants are followed up via telephone and there is one visit to the study site on day 30.\n\nHeart health is assessed based on the analysis of blood samples, which are collected at the study site, via electrocardiogram (ECG), echocardiogram and cardiac magnetic resonance (CMR) imaging. At the end of the study, the results are compared between the two groups. During the study, the doctors also regularly check the general health of the participants.",[25,288,289,290],"Reperfusion Injury","AMI","STEMI (ST Elevation MI)",[292,293],"STEMI","PCI","2026-07-07",{"date":296,"type":32},"2026-07-09",{"date":298,"type":32},"2026-07-02",{"date":127,"type":21},{"name":301,"class":130},"Nyrada Pty Ltd",7,{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":94,"phases":312,"briefSummary":313,"conditions":314,"keywords":315,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":328},"100643011","sixth-generation-high-sensitivity-cardiac-troponin-t-for-the-early-rule-out-of-myocardial-infarction-a-controlled-before-and-after-study-100643011","NCT07636642","Sixth Generation High-sensitivity Cardiac Troponin T for the Early Rule Out of Myocardial Infarction: a Controlled Before and After Study","STEREO-MI","Inclusion Criteria:\n\n* Age 18 years and over.\n* Attending clinician suspects acute coronary syndrome.\n* At least one measurement of cardiac troponin using the Gen 5 or Gen 6 hs-cTnT assay.\n\nExclusion Criteria:\n\n* Insufficient clinical information to perform record linkage.\n* Not resident in Scotland.\n* Previous enrolment in the study.",{"count":311,"type":21},19500,[96],"Cardiac troponin is a protein released into the blood when the heart muscle is damaged. Measuring this protein helps doctors diagnose a heart attack (also called a myocardial infarction). Modern blood tests, known as high-sensitivity cardiac troponin assays, can detect very small amounts of this protein.\n\nA new version of this test, called Troponin T high-sensitivity Gen 6, has recently been developed and approved for use. It is designed to be more accurate and reliable, detecting smaller changes in troponin levels and being less affected by technical interference. The investigators believe this improved test will allow doctors to diagnose heart attacks more quickly and decide sooner who needs to stay in hospital and who can safely go home. This could help reduce overcrowding in Accident and Emergency (A\\&E) departments, a major challenge for the NHS.\n\nThis study will examine whether switching to this new test across a health board shortens the time patients with suspected heart attacks spend in the Emergency Department. The investigators will use information from the DataLoch Heart Disease Registry, which automatically collects anonymised hospital data for patients attending with possible heart attacks. The investigators will compare data from one year before and one year after implementation to see whether average length of stay changes and to confirm that patient safety remains high. This investigators will also measure both the current and new versions of the troponin test in surplus blood samples collected during two six-month periods-one before and one after the new test is introduced. This will allows the investigators to directly compare the two tests reliably.\n\nPatients will not need to do anything extra to take part - the study uses information and samples already collected as part of their usual care.",[25],[316,73,317,318,319],"cardiac troponin","acute coronary syndrome","accelerated decision pathway","Troponin T high sensitivity generation six","2026-07-06",{"date":294,"type":32},{"date":323,"type":32},"2026-06-01",{"date":325,"type":21},"2029-05",{"name":327,"class":39},"University of Edinburgh",3,{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":94,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":352},"100612382","transcultural-digital-solutions-in-phase-iii-cardiac-rehabilitation-100612382","NCT07252856","Transcultural Digital Solutions in Phase III Cardiac Rehabilitation","CrOss-cultural Model for Postdischarge Assistance and Sustainable Digital Solutions in Phase III Cardiac Rehabilitation: a Randomized Controlled Trial","COMPASS","Inclusion Criteria:\n\n* Age ≥ 18, men and women;\n* patients with atherosclerotic cardiovascular disease (ASCVD) (acute coronary syndrome or chronic coronary syndrome and ischemic heart failure);\n* patients who completed phase II CR and are therefore eligible for CR phase III (maintenance).\n\nExclusion Criteria:\n\n* Unable to sign the informed consent;\n* unable or unwilling to use digital devices due to mental\u002Fcognitive issues or without a support person helping them to access the respective technical devices;\n* pregnant, lactating or women planning pregnancy during the course of the trial.",{"count":338,"type":21},306,[96],"Multicenter Prospective Controlled Randomized Trial, open-label, in patients with atherosclerotic cardiovascular disease (ASCVD) (acute coronary syndrome or chronic coronary syndrome and ischemic heart failure) and an approved indication for cardiac rehabilitation (CR). Patients completing phase II CR will be randomized 1:1 to usual Phase-III care (standard care) versus standard care plus the Digitally-Enhanced Extended PrEvention \\& Rehabilitation (DEEPER) package (intervention). Primary outcome is 6-month change in composite Life's Crucial 9 (LC9) (LE8 + PHQ-9).",[342,25],"Heart Failure","2026-06-26",{"date":345,"type":32},"2026-06-30",{"date":347,"type":32},"2026-04-20",{"date":349,"type":21},"2027-07-31",{"name":351,"class":39},"Fondazione Don Carlo Gnocchi Onlus",6,{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":361,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":94,"phases":364,"briefSummary":365,"conditions":366,"keywords":369,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":388},"100394478","phase-4-potassium-competitive-acid-blocker-versus-proton-pump-inhibitor-for-gastroprotection-strategies-in-patients-at-high-gastro-intestinal-bleeding-risk-receiving-antithrombotic-therapy-100394478","NCT04416581","Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy","A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease","PROTECT-HBR","Inclusion Criteria:\n\n1. Patients 19 years of age or older with known cardiac and vascular disease who are receiving chronic use of antithrombotic drugs (either antiplatelets, oral anticoagulant (OAC), and its combinations). Specific clinical conditions that may confer a need for long-term antithrombotic therapy may include documented coronary artery disease (stable or unstable angina, acute coronary syndrome, a history of myocardial infarction, or any coronary revascularization), documented cerebrovascular disease (stroke or transient ischemic attack), known peripheral arterial disease or a history of peripheral arterial revascularization, atrial fibrillation, or valvular heart disease requiring interventions (transcatheter aortic valve replacement or transcatheter mitral-valve repair). Concomitant use of a proton pump inhibitor is strongly recommended in patients receiving aspirin monotherapy, DAPT (dual antiplatelet therapy; aspirin plus any P2Y12 inhibitors), DAT (dual antithrombotic therapy; antiplatelet drug plus OAC), TAT (triple antithrombotic therapy; DAPT plus OAC), or OAC monotherapy (warfarin or direct oral anticoagulants) who are at high risk of GI bleeding in order to reduce the risk of gastric bleed or GI events. Based on clinical guidelines, the use of P2Y12 inhibitor monotherapy (i.e. clopidogrel, ticagrelor, or prasugrel) is not considered in trial enrollment.\n2. On the basis of clinical guidelines and expert consensus documents, we defined a study population with an increased risk of gastrointestinal bleeding if they had a least 1 or more criteria of the following characteristics. Eligible patients for randomization must meet at least 1 characteristic of these criteria:\n\n   \\*Definition of patients who are at high risk of gastrointestinal bleeding\n   1. Age ≥65 years\n   2. Concomitant use of OAC and any antiplatelet therapy (mono or DAPT) (i.e., DAT or TAT)\n   3. Long-term use of oral NSAIDs (non-steroidal anti-inflammatory drugs) or steroids or high-dose NSAID therapy even during a relatively short-term period.\n   4. History of prior GI bleeding events at any time\n   5. History of a previously complicated ulcer\n   6. History of peptic ulcer disease or a previously uncomplicated ulcer\n   7. Documented Helicobacter pylori infection\n3. Patients who voluntarily participated in the written agreement\n\nExclusion Criteria:\n\n1. Active bleeding at the time of inclusion or a history of hereditary or acquired hemostatic disorder\n2. Any clinical contraindication to using of antithrombotic therapies (antiplatelet agents or OAC)\n3. Concurrent use of PPI or P-CAB within 4 weeks before randomization\n4. Hemodynamically unstable conditions at the time of inclusion: cardiogenic shock at the time of randomization, refractory ventricular arrhythmias, or congestive heart failure (New York Heart Association class IV).\n5. Baseline severe anemia (Hgb \\\u003C8 g\u002Fdl at baseline) or transfusion within 4 weeks before randomization\n6. Baseline severe thrombocytopenia (platelet count \\\u003C50,000\u002Fmm3)\n7. Renal failure dependent on dialysis or severe renal insufficiency (creatinine clearance \\\u003C15 ml\u002Fmin)\n8. Severe chronic liver disease (defined as variceal haemorrhage, ascites, hepatic encephalopathy, or jaundice)\n9. Hypersensitivity or contraindication to PPI, P-CAB, any of the product components, or substituted benzimidazoles\n10. Use of clarithromycin and hypersensitivity to macrolide antibiotics for Helicobacter pylori eradication\n11. Concomitant use of clarithromycin with terfenadine, cisapride, astemizole, or pimozide for Helicobacter pylori eradication\n12. Systemic treatment with strong CYP 3A4 and p-glycoprotein (P-GP) inhibitors (e.g., systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus \\[HIV\\]-protease inhibitors, such as ritonavir)\n13. Patients who take atazanavir, nelfinavir, or rilpivirine-containing products (see Drug-Drug interaction section)\n14. Clinically significant laboratory abnormality at screening (estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin or elevated liver enzyme \\[AST, ALT, ALP, total bilirubin\\] \\> 3 times upper normal limit \\[UNL\\] or any other condition that, in the opinion of the Investigator, precludes participation in the study\n15. Any known or suspected malignancy\n16. Patients with non-cardiac co-morbidities with a life expectancy of less than 12 months\n17. Patients with active treatment for H-pylori infection\n18. Women who are pregnant or breastfeeding or female subjects, premenopausal who are not surgically sterile, or, if sexually active not practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and, for those of childbearing potential, who have a positive pregnancy test at screening\n19. Participation in another clinical study within 12 months. However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;\n\n    1. Participated in the observational study expected no effect on the safety and\u002For effectiveness evaluation of this trial\n    2. Screening failed before any interventional factor is involved\n    3. Participated in academic trials like strategic or medical device comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies","19 Years",{"count":363,"type":21},3320,[176],"The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known cardiac and vascular disease receiving chronic use of antithrombotic drugs (either antiplatelets, OAC, and its combinations) who are at high GI bleeding risk. The primary hypothesis is that P-CAB (experimental arm) would non-inferior to PPI (standard arm) with respect to the rate of the primary composite end point of GI events at 12 months after randomization.",[146,367,368,25],"Percutaneous Coronary Intervention","Acute Coronary Syndrome",[370,371,372,317,373,374,375,376,377,378,379],"gastroduodenal ulcer","gastrointestinal hemorrhage","peptic ulcer","coronary artery stent placement","antiplatelet","anticoagulant therapy","PPI","P-CAB","Proton-pump inhibitors","Potassium-Competitive Acid Blockers","2026-06-24",{"date":343,"type":32},{"date":383,"type":32},"2021-05-12",{"date":385,"type":21},"2028-02-28",{"name":387,"class":39},"Duk-Woo Park, MD",45,{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":397,"targetDuration":398,"studyType":22,"phases":4,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":40},"100636249","polymer-free-sirolimus-eluting-stent-real-world-investigation-of-safety-and-outcomes-100636249","NCT07563231","Polymer-free Sirolimus Eluting Stent: Real-world Investigation of Safety and Outcomes","POLARIS : POLymer-free Sirolimus Eluting Stent: Real-world Investigation of Safety and Outcomes","POLARIS","Inclusion Criteria:\n\n* Age \\>= 18 years at the time of the index procedure.\n* Percutaneous coronary intervention performed at Geneva University Hospitals between January 2021 and December 2025.\n* Implantation of at least one study device\n* Indication for PCI according to current European or American guidelines.\n* Able and willing to provide written informed consent.\n* Sufficient knowledge of French, German, English, or Italian to understand the patient information document.\n\nExclusion Criteria:\n\n* Documented refusal to participate in research through opt-out from general consent.\n* Inability to provide informed consent (cognitive impairment or other).\n* Inability to be contacted for informed consent (no valid contact information, or unreachable after three contact attempts).\n* Life expectancy less than 12 months due to non-cardiac comorbidities at the time of consent.\n* Participation in another clinical trial that would interfere with the endpoints of this registry.",{"count":20,"type":21},"5 Years","POLARIS is a prospective, single-centre, single-arm observational pilot registry evaluating the real-world safety and efficacy of the Focus np (Abluminus np, Concept Medical, Tampa, FL, USA) polymer-free sirolimus-eluting stent in consecutive adult patients undergoing percutaneous coronary intervention (PCI). The primary endpoint is target lesion failure (TLF) at 12 months, defined per Academic Research Consortium-2 (ARC-2) criteria as the device-oriented composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularisation. Patients treated since January 2021 will be retrospectively identified and prospectively consented, with follow-up through 5 years. The registry will provide the first Western clinical evidence on this CE-marked device and serve as a template for a future national Swiss multicentre registry.",[146,368,25,401,367],"Stent Thrombosis",[403,404,405,406,407,408,409],"drug-eluting stent","polymer-free stent","sirolimus","percutaneous coronary intervention","target lesion failure","registry","real-world evidence","2026-06-05",{"date":412,"type":32},"2026-06-09",{"date":414,"type":21},"2026-06",{"date":416,"type":21},"2036-06",{"name":418,"class":39},"Dorian Garin",{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":94,"phases":428,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":445,"locationsCount":40},"100634540","teleheartcr-vs-clinic-based-cardiac-rehabilitation-after-acute-coronary-syndrome-100634540","NCT07541014","TeleheartCR vs. Clinic-Based Cardiac Rehabilitation After Acute Coronary Syndrome","Comparing a Novel Telehealth-enabled Hybrid Cardiac Rehabilitation Program to Clinic-based Cardiac Rehabilitation for Improving Patient Engagement and Functional Outcomes After ACS","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of acute coronary syndrome within the past 12 months\n* Eligible for outpatient cardiac rehabilitation\n* Able to read and speak English or Spanish\n* Resides in New York State\n\nExclusion Criteria:\n\n* Severe medical or psychiatric comorbidities that would prevent safe or adequate participation\n* High risk for adverse exercise-related cardiovascular events\n* Initiation of cardiac rehabilitation prior to enrollment (i.e., \\>1 session completed)\n* Conditions that would interfere with safe or consistent participation in study procedures\n* Home environment or willingness not compatible with safe or adequate participation\n* Not expected to be available for follow-up during the study period\n* Current participation in another interventional clinical trial that may affect study outcomes",{"count":427,"type":21},250,[96],"Cardiac rehabilitation (CR) is an effective evidence-based intervention that improves outcomes in patients with acute coronary syndrome (ACS), but many eligible patients do not complete the program. A hybrid CR intervention that combines telehealth, home-based, and clinic-based components (TeleheartCR) may increase participation by addressing barriers to access while maintaining the functional capacity benefits of traditional CR. The purpose of this study is to conduct a randomized controlled trial comparing TeleheartCR with traditional clinic-based CR in patients with ACS to evaluate differences in program adherence and pre-to-post program change in functional capacity.",[431,25],"Acute Coronary Syndrome (ACS)",[214,433,434,435,436,437,438],"Hybrid Cardiac Rehabilitation","Virtual Cardiac Rehabilitation","Implementation Science","Adherence","Functional Capacity","Telehealth","2026-05-30",{"date":441,"type":32},"2026-06-03",{"date":443,"type":32},"2026-05-19",{"date":325,"type":21},{"name":446,"class":39},"Columbia University",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":457,"conditions":458,"keywords":472,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":495},"100569808","ai-enabled-direct-from-ecg-ejection-fraction-ef-severity-assessment-using-cor-ecg-wearable-monitor-100569808","NCT06699056","AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor","AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Using COR ECG Wearable Monitor","EFACT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able and eligible to wear a Holter monitor\n\nExclusion Criteria:\n\n* Receiving mechanical respiratory or circulatory support, or renal support therapy, at the time of screening or during Visit #1\n* Any condition that, in the investigator's opinion, could interfere with compliance with the study protocol or pose a safety risk to the participant\n* History of poor tolerance or severe skin reactions to ECG adhesive materials",{"count":456,"type":21},2000,"This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF) severity categories based on the American Society of Echocardiography's (ASE) 4-category scale. The software analyzes continuous ECG waveform data acquired by the FDA-cleared Peerbridge COR® ECG Wearable Monitor, an ambulatory patch device designed for use during daily activities. The AI software assists clinicians in cardiac evaluations by estimating EF severity, which reflects how well the heart pumps blood.\n\nIn this study, EF severity determination will be made using 5-minute ECG recordings collected during a 15-minute resting period with participants seated upright. The results will be compared to EF severity obtained from an FDA-cleared, non-contrast transthoracic echocardiogram (TTE) predicate device. This comparison aims to validate the accuracy of the AI software.",[459,460,461,462,463,342,464,465,466,25,467,468,469,470,471],"Ventricular Ejection Fraction","LVF","LV Dysfunction","Atrial Enlargement","Conduction Defect","Valvular Heart Disease","Ischemic Heart Disease","Cardiotoxicity","Dilated Cardiomyopathy","HFrEF - Heart Failure With Reduced Ejection Fraction","HFpEF - Heart Failure With Preserved Ejection Fraction","Syncope","Remodeling, Cardiac",[473,474,475,476,477,478,479,461,480,481,482,483,484,485,462,486],"ECG Patch","LVEF","Holter","ECG Wearable","COR","Atrial Conduction","ECG Biomarker","SaMD","Clinical Decision Support","ECG","EF Severity","Ejection Fraction","AI","Electrical Remodeling","2026-05-28",{"date":323,"type":32},{"date":490,"type":32},"2024-11-21",{"date":492,"type":21},"2027-11-15",{"name":494,"class":130},"Peerbridge Health, Inc",8,{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":515,"leadSponsor":517,"locationsCount":40},"100637765","machine-learning-for-diagnosis-of-occlusive-mi-in-lbbb-patients-100637765","NCT07620119","Machine Learning for Diagnosis of Occlusive MI in LBBB Patients","Development of a Machine Learning Model for the Diagnosis of Occlusive Myocardial Infarction in the Setting of Left Bundle Branch Block","AI-LBBB","Inclusion Criteria:\n\n* Patients aged 18 years and older who present to the emergency department. Patients presenting with acute ischemic chest pain or clinical ischemia-equivalent symptoms (such as acute dyspnea, unexplained diaphoresis, or syncope).\n\nPatients with a confirmed Left Bundle Branch Block (LBBB) on their initial 12-lead electrocardiogram (ECG), which can be either newly developed or known\u002Fchronic.\n\nPatients who undergo invasive coronary angiography during their index hospital admission.\n\nPatients or their legally authorized representatives who provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients under the age of 18. Pregnant or lactating women. Patients with poor-quality or uninterpretable digital ECG recordings due to severe artifact, missing leads, or technical errors.\n\nPatients who develop cardiopulmonary arrest before an initial diagnostic 12-lead ECG can be obtained in the emergency department.\n\nPatients transferred from another healthcare facility who have already undergone coronary angiography or revascularization.\n\nPatients who decline to participate or refuse to provide written informed consent.",{"count":67,"type":21},"This study investigates a new way to diagnose severe heart attacks in patients who have a specific electrical heart pattern called a Left Bundle Branch Block (LBBB). When patients present to the emergency department with chest pain, doctors routinely perform an electrocardiogram (ECG) to check for a heart attack. However, the presence of an LBBB can alter the heart's electrical signals on the ECG, effectively masking or hiding the typical signs of an ongoing acute coronary occlusion (a completely blocked artery). This making it highly challenging for emergency physicians to make an accurate and rapid diagnosis.\n\nThe primary purpose of this prospective and observational research is to develop and evaluate an artificial intelligence\u002Fmachine learning (ML) model that can analyze digital 12-lead ECG signals to accurately predict a true blocked coronary artery in patients with LBBB. The machine learning model will analyze raw digital ECG waveforms to detect subtle, microscopic patterns that might be missed by the human eye.\n\nTo confirm the accuracy of the model, its predictions will be compared directly with invasive coronary angiography results, which is the gold standard reference method used to visualize blocked vessels. Additionally, the study aims to evaluate if the model can differentiate between a true heart attack caused by a blocked artery (Type 1 MI) and other non-occlusive conditions that cause elevated heart enzymes (Type 2 MI). Ultimately, the investigators intend to determine whether integrating this machine learning tool into emergency care can safely reduce the rate of unnecessary emergency invasive procedures for patients who do not have a true coronary blockage.",[507,508,509,510,25],"Acute Myocardial Infarction (AMI)","Left Bundle Branch Block","Coronary Occlusion\u002FThrombosis","Chest Pain","2026-05-22",{"date":513,"type":32},"2026-06-02",{"date":323,"type":21},{"date":516,"type":21},"2027-01-31",{"name":518,"class":39},"Konya City Hospital",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":94,"phases":527,"briefSummary":528,"conditions":529,"keywords":535,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":40},"100640061","phase-4-pre-discharge-influenza-vaccination-in-patients-hospitalized-for-acute-cardiac-conditions-100640061","NCT07617376","Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions","Inclusion Criteria:\n\n* Acute cardiac hospitalization,\n* Planned discharge home within the next 48 hours following completion of in-hospital treatment,\n* No prior influenza vaccination for the current influenza season.\n\nExclusion Criteria:\n\n* History of a severe adverse reaction to influenza vaccination,\n* Allergy to any component of the vaccine to be administered,\n* Discharge to another hospital for continuation of treatment or discharge to a long-term care facility,\n* Antibiotic therapy to be continued after discharge.",{"count":526,"type":21},400,[176],"Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge.\n\nIn this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.",[25,530,531,532,533,534],"Decompensated Chronic Heart Failure","Acute Heart Failure (AHF)","Pulmonary Embolism Acute","Hypertension Emergency","Arrhythmias",[536,537,538],"influenza vaccination","acute cardiac emergencies","pre-discharg vaccination","2026-05-20",{"date":323,"type":32},{"date":542,"type":32},"2025-11-12",{"date":544,"type":21},"2027-07-01",{"name":546,"class":39},"Wroclaw Medical University",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":94,"phases":556,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":573},"100500266","cohort-of-stemi-patients-2-100500266","NCT05794022","Cohort of STEMI Patients 2","CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction","HIBISCUS STEMI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG.\n* Management in primary ACT\n* Prior oral informed consent followed by signed informed consent as soon as possible.\n\nExclusion Criteria:\n\n* Diagnosis of STEMI not confirmed on angiography\n* Inability to give the subject informed information\n* Lack of coverage by a social security scheme\n* Obvious contraindication to injected magnetic resonance imaging (claustrophobia, pacemaker, defibrillator, or a metallic body (ferromagnetic), severe renal insufficiency (GFR\\\u003C30 ml\u002Fmin), known allergy to the contrast medium ....)\n* Pregnant woman or woman of childbearing age without effective contraception, breastfeeding woman.\n* Deprivation of civil rights (curators, guardianship, safeguard of justice)",{"count":20,"type":21},[96],"ST-segment elevation myocardial infarction (STEMI) is an acute condition that accounts for 75% of sudden deaths in adults over 35 years of age and more than half of all cases of chronic heart failure. However, the mechanism of myocardial infarction remains poorly understood. At present, there is no national information system for myocardial infarction, as there is for other diseases such as multiple sclerosis (OFSEP cohort).\n\nThe purpose of this cohort is to enable studies and research projects to be carried out on the descriptive epidemiology of myocardial infarction, monitoring of patients undergoing treatment (safety, efficacy), quality of life and functional consequences of infarction, and research into new biological and imaging prognostic biomarkers. Its general objective is to provide researchers, hospital practitioners, medical interns, academics or industrialists with a quality epidemiological tool for research.",[25],[118,560,561,562,292,563],"bio-collection","Imaging markers","biomarkers","clinical outcomes","2026-05-13",{"date":566,"type":32},"2026-05-14",{"date":568,"type":32},"2023-05-03",{"date":570,"type":21},"2033-06-03",{"name":572,"class":39},"Hospices Civils de Lyon",2,{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":17,"minAge":361,"maxAge":4,"enrollmentInfo":582,"targetDuration":584,"studyType":22,"phases":4,"briefSummary":585,"conditions":586,"keywords":589,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":40},"100460207","coronary-microvascular-dysfunction-assessments-in-myocardial-infarction-with-non-obstructive-coronary-arteries-100460207","NCT05272618","Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries","Clinical Relevance of Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries","CMD-MINOCA","Inclusion Criteria:\n\n* Subject with age ≥19 years and acute myocardial infarction\n\n  * Rise and\u002For fall of cardiac troponin with one level \\>99 percentile plus ischemic signs\u002Fsymptoms\n\n    * Subject with non-obstructive coronary arteries\n  * \\\u003C50% diameter stenosis or\n  * fractional flow reserve (FFR) \\>0.80 ③ Subject without previous history of coronary artery disease\n\n    * Subject who performed invasive coronary angiography within 24 hours after presentation ⑤ Subject who eligible for invasive and non-invasive coronary physiologic assessment\n\nExclusion Criteria:\n\n* Subject with obstructive coronary arteries\n\n  * Subject with alternate diagnosis including sepsis, pulmonary embolism, myocarditis, Takotsubo syndrome, spontaneous coronary dissection, and other cardiomyopathies.\n\n    * Subject with cardiogenic shock or cardiac arrest ④ Subject who has non-cardiac co-morbid conditions with life expectancy \\\u003C1 year ⑤ Subject or lactating women ⑥ Subject unable to provide consent",{"count":583,"type":21},150,"12 Months","To compare clinical outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA) according to the coronary microvascular dysfunction (CMD), evaluated by optical coherence tomography (OCT), invasive and non-invasive coronary physiologic assessment.",[25,587,588],"Coronary Microvascular Dysfunction","Vasospasm, Coronary",[590,591,592,593,594,595],"MINOCA","Coronary physiology","Cardiac PET","CFR","IMR","OCT","2026-05-08",{"date":598,"type":32},"2026-05-12",{"date":600,"type":32},"2022-02-14",{"date":602,"type":21},"2030-12-31",{"name":604,"class":39},"Chonnam National University Hospital",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":259,"enrollmentInfo":612,"targetDuration":4,"studyType":94,"phases":614,"briefSummary":615,"conditions":616,"keywords":619,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":40},"100414125","emdr-treatment-in-ptsd-following-cardiac-events-100414125","NCT04672551","EMDR Treatment in PTSD Following Cardiac Events","EMDR_PTSD_MI","Inclusion Criteria:\n\n* Age between 18-70 years\n* Men or women\n* STEMI (irrespective of troponin, but ST-elevation) or non-STEMI (troponin positive) at the time of the cardiac event, as verified by the cardiologist\n* Diagnosis of PTSD caused by the cardiac event\n\nExclusion Criteria:\n\n* Psychotic disorder, bipolar disorder, substance abuse as measured with the Mini International Neuropsychiatric Interview (M.I.N.I)\n* Acute suicidal ideation as assessed with the M.I.N.I.\n* Non-selective beta blockers (e.g., propranolol) during the study period\n* Ongoing psychological\u002Fpsychiatric treatment outside of the trial during the study period\n* Visionary problems, e.g. strabismus, which does not allow adequate eye movements\n* Insufficient knowledge of the German language\n* Expected inability or willingness to follow the study protocol\n* Regular medication with benzodiazepine",{"count":613,"type":21},60,[96],"Cardiac events can often result in debilitating and persistent psychological symptoms. A key question involves whether optimal treatment of cardiac-induced posttraumatic stress disorder (PTSD) reduces PTSD symptoms and thereby may offset the risk of recurrent or worsening cardiovascular disease. Cardiac-induced PTSD 1) is prevalent, 2) features symptoms unique to internal ongoing somatic threat, with fears and worries that can be distinguished from PTSD resulting from external causes, 3) is persistent, 4) is associated with negative physical and emotional consequences, and 5) has not been the subject of randomized-controlled treatment trials (RCT). There is preliminary evidence suggesting that patients with cardiac-disease induced PTSD might particularly profit from EMDR. Nevertheless, this possibility has not been tested in cardiac-induced PTSD. Currently, patients with cardiac-induced PTSD are not routinely offered trauma-focused therapies, with a lack of scientific evidence likely being one major reason for this omission. If our proposed RCT shows that EMDR can be an effective treatment for patients with ACS-induced PTSD, EMDR could be routinely implemented as first-line treatment. The RCT outcomes might inform larger trials to test whether poor prognosis in terms of major adverse cardiovascular events can be improved through EMDR in patients with cardiac-induced PTSD.",[617,25,618],"Posttraumatic Stress Disorder","Eye Movement Desensitization and Reprocessing",[620,232,621,622],"PTSD","ACS","EMDR","2026-05-06",{"date":625,"type":32},"2026-05-07",{"date":627,"type":32},"2020-11-21",{"date":629,"type":21},"2027-11-30",{"name":631,"class":39},"University of Zurich",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":17,"minAge":361,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":94,"phases":642,"briefSummary":643,"conditions":644,"keywords":646,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":131},"100533587","oct-versus-angiography-for-culprit-lesion-revascularization-in-acute-myocardial-infarction-patients-100533587","NCT06227754","OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts","Randomized Controlled Trial of Optical Coherence Tomography Versus Angiography for Culprit Lesion Revascularization in Patients With Acute Myocardial Infarction","FRAME-AMI3","Inclusion Criteria:\n\n* Subject must be at least 19 years of age\n* Acute ST-segment elevation myocardial infarction (STEMI)\n\n  \\*STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block1\n* Primary percutaneous coronary intervention (PCI) in \\\u003C 12 h after the onset of symptoms for STEMI patients\n* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* Target lesions not amenable for PCI by operators' decision\n* Ostial lesions located in left main vessel or right coronary artery (left main body or distal bifurcation lesions can be enrolled by operator's discretion)\n* Creatinine clearance ≤30 ml\u002Fmin\u002F1.73 m2 and not on dialysis (chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance)\n* Cardiogenic shock (Killip class IV) at presentation\n* Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus\n* Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)\n* Pregnancy or breast feeding\n* Non-cardiac co-morbid conditions are present with life expectancy \\\u003C2 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n* Unwillingness or inability to comply with the procedures described in this protocol",{"count":641,"type":21},1500,[96],"The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).",[645,25],"ST Elevation Myocardial Infarction",[647,648,649,650],"ST-segment elevation MI","Optical coherence tomography","Intravascular imaging","Primary PCI","2026-05-05",{"date":596,"type":32},{"date":654,"type":32},"2024-03-25",{"date":656,"type":21},"2031-12-31",{"name":604,"class":39},{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":664,"eligibilityCriteria":665,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":666,"targetDuration":4,"studyType":94,"phases":668,"briefSummary":669,"conditions":670,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":40},"100402548","examination-of-the-impact-of-calmigos-stress-management-device-on-vascular-heath-and-cardiovascular-disease-risk-100402548","NCT04521699","Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.","Examination of the Impact of CalmiGo's Stress Management Device on Vascular Health and Cardiovascular Disease Risk , and Markers of Mental Stress in Patients Following a Myocardial Infarction Participating in Clinically Indicated Cardiac Rehabilitation","CalmiGo","Inclusion Criteria:\n\n* 18 years of age or older\n* Ability to use the CamliGo device for 12-weeks\n* Willingness to complete study questionnaires, blood tests,\\& EndoPat testing at the beginning and end of study\n* Patients who have had a recent MI who will be undergoing clinically indicated Cardiac Rehabilitation\n* Patients who have had a coronary or structural intervention performed in the cardiac catheterization laboratory within the last month, including: coronary stenting; coronary balloon angioplasty; transcatheter aortic valve replacement; mitral valve interventions; patent foramen ovale closures; alcohol septal ablation; paravalvular leak closure.\n* Patients being seen in the Chest Pain Clinic for Atypical chest pain\n\nExclusion Criteria:\n\n* Cognitively impaired patients\n* Patient with Bipolar disorder, psychosis or delusional disorder\n* History of substance abuse or dependence\n* History of suicidality\n* Unstable cardiovascular or pulmonary disease\n* History of seizures\n* Latex allergy",{"count":667,"type":21},100,[96],"The primary purpose of this study is to determine if there are significant differences with respect to baseline between those randomized to CGo and standard-of-care versus standard-of-care alone after completing 12-weeks of therapy in terms of peripheral endothelial function measured by EndoPAT.",[25],"2026-04-29",{"date":651,"type":32},{"date":674,"type":32},"2022-01-13",{"date":676,"type":21},"2026-12",{"name":678,"class":39},"Mayo Clinic",{"id":680,"slug":681,"hasResults":12,"nctId":682,"briefTitle":683,"officialTitle":684,"acronym":685,"eligibilityCriteria":686,"healthyVolunteers":16,"sex":17,"minAge":687,"maxAge":4,"enrollmentInfo":688,"targetDuration":4,"studyType":94,"phases":689,"briefSummary":690,"conditions":691,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":692,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":697,"locationsCount":573},"100397727","the-next-leap-in-cardiac-magnetic-resonance-imagingcycling-the-field-100397727","NCT04458883","The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field","The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field The TITAN Study","TITAN","Inclusion Criteria:\n\n* Participant who is willing and able to give informed consent for participation in the study\n* Healthy volunteers willing to give informed consent for participation in the study\n* Patients diagnosed with a previous myocardial infarction\n\nExclusion Criteria:\n\n* Unwillingness to participate\n* Claustrophobia\n* Contraindication to MRI scanning such as implantable cardiac devices\n* Participants who have had a previous myocardial infarction in the past of which they may not be aware and this is discovered whilst being scanned on the 3T MRI scanner, or who may have any other cardiology condition that they were previously unaware will not be included in the healthy control group, even if they present themselves to us as \"healthy\" at the time of the study visit\n* Pregnancy\n* Body habitus that may preclude comfortable positioning of the volunteer in either of the MRI scanners (\\>50cm in diameter)\n* Participants with abnormal kidney function that will preclude them from receiving a contrast agent","20 Years",{"count":583,"type":21},[96],"The main aim of the study is to build and test a cardiac-specific coil purposely assembled in house to suit the FFC-MRI whole-body prototype and to test if it could be used for clinical cardiac scans in human subject populations.",[25],{"date":693,"type":32},"2026-04-30",{"date":695,"type":32},"2020-08-01",{"date":349,"type":21},{"name":698,"class":39},"University of Aberdeen"]